The cost is significantly less than the injection
-
Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments that have reshaped the obesity market.
-
The daily pill is designed to offer comparable weight-loss benefits to injections while lowering barriers for patients hesitant about needles.
-
Analysts say the move could intensify competition in a market already dominated by blockbuster GLP-1 drugs and reshape how obesity is treated in primary care.
Novo Nordisk has announced the U.S. launch of its long-anticipated GLP-1 weight-loss pill, marking a significant step in the companys effort to broaden access to obesity treatment and defend its leadership in one of the fastest-growing segments of the pharmaceutical industry.
The once-daily pill, which targets the same hormonal pathway as injectable GLP-1 drugs, is intended for adults with obesity or overweight conditions linked to health risks such as diabetes and heart disease. The drug will be marketed as the Wegovy Pill.
By offering an oral alternative, Novo Nordisk aims to reach patients who have been unwilling or unable to use weekly injections, which have powered the companys recent growth.
An effective oral option has the potential to change how obesity is treated in everyday clinical practice, Novo Nordisk said in a statement announcing the launch, adding that the pill is meant to complementnot replaceits injectable portfolio.
According to CNBC, the cash price of the pill is among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. GLP-1 injectable drugs cost significantly more.
How the drugs work
GLP-1 medications work by mimicking hormones that regulate appetite and blood sugar, helping patients feel fuller for longer. Injectable versions have delivered dramatic weight-loss results but have also faced supply constraints, high prices, and uneven insurance coverage. Novo Nordisk says the pill could ease some of those pressures by simplifying manufacturing and prescribing.
Still, the company cautioned that the pill is not a shortcut. As with injectable therapies, it is intended to be used alongside diet and lifestyle changes, and patients may experience side effects such as nausea during the early stages of treatment.
The U.S. launch comes as competition in the GLP-1 space intensifies. Rival drugmakers are racing to develop next-generation injectables and oral alternatives, while insurers and employers weigh the long-term costs of covering weight-loss drugs for millions of patients.
For Novo Nordisk, the pill represents both an opportunity and a defensive move. Analysts say success could significantly expand the overall market for obesity treatment, while failure could leave the company vulnerable to competitors with more convenient or cheaper options.
Novo Nordisk said it expects a gradual rollout in the coming months, with pricing and insurance coverage varying by plan. The company declined to provide sales forecasts but said that it views oral GLP-1 therapy as a critical pillar of its long-term strategy in obesity care.
Posted: 2026-01-05 14:30:08



















